US Penny Stocks To Consider In December 2024

As the U.S. stock market experiences a rise in anticipation of the Federal Reserve's upcoming meeting, with the Nasdaq hitting record highs, investors are exploring diverse opportunities across various sectors. Penny stocks, though often seen as remnants of past market trends, continue to offer intriguing possibilities for those seeking growth at lower entry points. By focusing on smaller or newer companies with strong financials and potential for expansion, investors can uncover valuable opportunities within this segment of the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.63	$2.03B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$128.29M	★★★★★★
BAB (OTCPK:BABB)	$0.8695	$6.32M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.96	$89.78M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.224099	$8.25M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.48	$48.84M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$0.755	$13.39M	★★★★★☆
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8405	$75.59M	★★★★★☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Veru (NasdaqCM:VERU)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Veru Inc. is a late clinical stage biopharmaceutical company that develops medicines for metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS), with a market cap of $105.79 million.

Operations: The company's revenue is primarily derived from its FC2 segment, totaling $14.09 million.

Market Cap: $105.79M

Veru Inc., with a market cap of US$105.79 million, is currently unprofitable and has faced increased losses over the past five years. Despite this, the company shows potential with forecasted revenue growth of 40.82% annually. Recent analysis highlights a reduction in debt to equity ratio and sufficient short-term assets to cover liabilities, indicating some financial stability. However, Veru's cash runway is less than a year if current free cash flow trends continue. The company recently withdrew its US$6.15 million shelf registration filing but presented promising data on enobosarm at recent conferences, showcasing its potential in obesity treatment research.

• Navigate through the intricacies of Veru with our comprehensive balance sheet health report here.
• Understand Veru's earnings outlook by examining our growth report.

Duluth Holdings (NasdaqGS:DLTH)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Duluth Holdings Inc. operates in the United States, selling casual wear, workwear, outdoor apparel, and accessories for men and women under the Duluth Trading brand, with a market cap of approximately $120.31 million.

Operations: The company's revenue from online retail sales amounts to $630.97 million.

Market Cap: $120.31M

Duluth Holdings faces challenges as it remains unprofitable, with increasing losses over the past five years. Recent earnings reports show a decline in sales to US$127.06 million for Q3 2024, down from US$138.21 million a year ago, and a net loss of US$28.54 million compared to US$10.47 million previously. Despite this, Duluth's short-term assets of US$264.3 million exceed both its short-term and long-term liabilities, suggesting some balance sheet strength. The management team has an average tenure of 3.6 years, indicating experience amidst recent executive changes that could impact future strategic direction.

• Click here and access our complete financial health analysis report to understand the dynamics of Duluth Holdings.
• Gain insights into Duluth Holdings' future direction by reviewing our growth report.

Flexible Solutions International (NYSEAM:FSI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Flexible Solutions International, Inc. develops, manufactures, and markets specialty chemicals designed to reduce water evaporation across Canada, the United States, and internationally with a market cap of approximately $49.20 million.

Operations: The company's revenue is primarily derived from Biodegradable Polymers (TPA) at $37.87 million and Energy and Water Conservation Products (EWCP) at $0.63 million.

Market Cap: $49.2M

Flexible Solutions International demonstrates financial stability with its net profit margins improving to 10.8% and debt well covered by operating cash flow. The company has shown earnings growth of 12.6% over the past year, outpacing the chemicals industry average, and maintains a low price-to-earnings ratio of 11.8x compared to the broader US market. Despite an unstable dividend track record, its short-term assets significantly exceed liabilities, providing liquidity strength. Recent auditor changes have not affected financial statement integrity as previous reports were unqualified. Earnings for Q3 2024 showed a positive turnaround with net income of US$0.61 million from a prior loss.

• Click here to discover the nuances of Flexible Solutions International with our detailed analytical financial health report.
• Explore Flexible Solutions International's analyst forecasts in our growth report.

Key Takeaways

• Explore the 720 names from our US Penny Stocks screener here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com